• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Jasper Therapeutics Inc.

    5/19/25 8:02:13 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $JSPR alert in real time by email
    DEFA14A 1 ea0241493-02.htm DEFINITIVE ADDITIONAL MATERIALS

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    ________________________________

    SCHEDULE 14A INFORMATION

    ________________________________

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934 (Amendment No.   )

    Filed by the Registrant

     

    ☒

    Filed by a Party other than the Registrant

     

    ☐

    Check the appropriate box:

    ☐

     

    Preliminary Proxy Statement

    ☐

     

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

     

    Definitive Proxy Statement

    ☒

     

    Definitive Additional Materials

    ☐

     

    Soliciting Material under §240.14a-12

    JASPER THERAPEUTICS, INC.
    (Name of Registrant as Specified In Its Charter)

    N/A
    _____________________________________________________________
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒

     

    No fee required.

    ☐

     

    Fee paid previously with preliminary materials.

    ☐

     

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

    2025 You May Vote Your Proxy When You View The Material On The Internet. You Will Be Asked To Follow The Prompts To Vote Your Shares. Jasper Therapeutics, Inc. 2200 Bridge Pkwy Suite #102 Redwood City, CA 94065 Jasper Therapeutics, Inc. c/o Continental Proxy Services 1 State Street, New York NY 10004 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS to be held on July 3, 2025 *Stockholders are cordially invited to attend the Annual Meeting and vote in person. At the meeting, you will need to request a ballot to vote your shares. Dear Stockholder, The 2025 Annual Meeting of Stockholders of Jasper Therapeutics, Inc. will be held virtually at https://cstproxy.com/JasperTherapeutics/2025 on Thursday, July 3, 2025, at 10:00 a.m. Pacific Time. Proposals to be considered at the Annual Meeting: (1) Election of three Class I directors to serve until the 2028 annual meeting of stockholders; (2) Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025; (3) Advisory vote on approval of the compensation of the named executive officers; and (4) Advisory vote on the frequency of future advisory votes on executive compensation. The Board of Directors recommends a vote “FOR” all nominees under Proposal 1, “FOR” Proposals 2 and 3 and “ONE YEAR” for Proposal 4. Your electronic vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed, dated, and returned the proxy card. Vote during the Meeting – If you plan to attend the virtual online Annual Meeting, you will need your 12 digit control number to vote electronically during the annual meeting. To attend the annual meeting, visit: https://www.cstproxy.com/JasperTherapeutics/2025 Vote Your Proxy on the Internet: Go to http://www.cstproxyvote.com Have your notice available when you access the above website. Follow the prompts to vote your shares. CONTROL NUMBER The Proxy Materials are available for review at: https://www.cstproxy.com/JasperTherapeutics/2025

     

    2025 Jasper Therapeutics, Inc. 2200 Bridge Pkwy Suite #102 Redwood City, CA 94065 Important Notice Regarding the Availability of Proxy Materials for the 2025 Annual Meeting of Stockholders to be Held On Thursday, July 3, 2025 The following Proxy Materials are available to you to review at: https://www.cstproxy.com/JasperTherapeutics/2025 - the Company’s Annual Report on Form 10-K for the year ended December 31, 2024; - the Company’s 2025 Proxy Statement; - the Proxy Card; and - any amendments to the foregoing materials that are required to be furnished to stockholders. This is not a ballot. You cannot use this notice to vote your shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. If you would like to receive a paper or e-mail copy of these documents, you must request one. There is no charge for such documents to be mailed to you. Please make your request for a copy as instructed below on or before June 19, 2025 to facilitate a timely delivery. You may also request that you receive paper copies of all future proxy materials from the Company. ACCESSING YOUR PROXY MATERIALS ONLINE Have this notice available when you request a paper copy of the proxy materials or to vote your proxy electronically. You must reference your Control number. REQUESTING A PAPER COPY OF THE PROXY MATERIALS By telephone please call 1-888-266-6791, or By logging on to https://www.cstproxy.com/JasperTherapeutics/2025 or By email at: [email protected] Please include the company name and your control number in the subject line.

     

    Get the next $JSPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JSPR

    DatePrice TargetRatingAnalyst
    2/13/2025$38.00Buy
    UBS
    12/6/2024$63.00Outperform
    BMO Capital Markets
    9/9/2024$70.00Mkt Outperform
    JMP Securities
    7/8/2024$90.00Buy
    BTIG Research
    6/27/2024$86.00Buy
    Stifel
    5/6/2024$65.00Buy
    H.C. Wainwright
    4/3/2024$65.00Outperform
    Evercore ISI
    3/28/2024$70.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $JSPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Jasper Therapeutics to Present at Upcoming Investor Conferences

      REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate in the following investor conferences: RBC Capital Markets 2025 Global Healthcare Conference Conference Dates: May 20-21, 2025Presentation Date/Time: Wednesday, May 21, 2025; 11:00 a.m. EDTPresentation Format: Fireside Chat Jefferies 2025 Global Healthcare ConferenceConference Dates: June 3-5,

      5/14/25 4:30:00 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

      REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is presenting updated clinical data from the Phase 1b/2a BEACON study, as well as data from four preclinical studies evaluating briquilimab, at the AAAAI 2025 Annual Meeting, being held February 28 - March 3, 2025, in San Diego, CA. The BEACON update, based on a data-cut date of January 31, 2025, features approximately one month of additio

      3/1/25 12:45:13 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

      REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced a late-breaking oral presentation of briquilimab data from the Phase 1b/2a BEACON in CSU study at the 2025 AAD Annual Meeting, being held March 7 - 11, 2025, in Orlando, FL. The presentation will consist of data from patients included in the Company's January 8th, 2025, disclosure of preliminary data from the BEACON study.

      2/28/25 8:00:59 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JSPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Carlyle Group Inc. bought $2,460,500 worth of Voting Common Stock (190,000 units at $12.95) (SEC Form 4)

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      2/12/24 6:23:53 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Velan Capital Investment Management Lp bought $4,532,500 worth of shares (350,000 units at $12.95) (SEC Form 4)

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      2/9/24 8:40:05 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wiggans Thomas G bought $6,486 worth of Voting Common Stock (10,000 units at $0.65), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      11/30/23 4:05:16 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JSPR
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Jasper Therapeutics Inc.

      DEFA14A - Jasper Therapeutics, Inc. (0001788028) (Filer)

      5/19/25 8:02:13 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Jasper Therapeutics Inc.

      DEF 14A - Jasper Therapeutics, Inc. (0001788028) (Filer)

      5/19/25 8:00:17 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)

      5/12/25 4:05:08 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JSPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Jasper Therapeutics with a new price target

      UBS initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $38.00

      2/13/25 8:09:46 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BMO Capital Markets initiated coverage on Jasper Therapeutics with a new price target

      BMO Capital Markets initiated coverage of Jasper Therapeutics with a rating of Outperform and set a new price target of $63.00

      12/6/24 7:52:11 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on Jasper Therapeutics with a new price target

      JMP Securities initiated coverage of Jasper Therapeutics with a rating of Mkt Outperform and set a new price target of $70.00

      9/9/24 7:39:14 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JSPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

      SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

      11/14/24 6:01:49 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

      SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

      11/14/24 3:32:57 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

      SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

      11/4/24 12:05:53 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JSPR
    Leadership Updates

    Live Leadership Updates

    See more
    • Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

      REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced the appointment of Svetlana Lucas, Ph.D., to Jasper's Board of Directors (the Board), effective as of June 18, 2024. Separately, Anna French, D. Phil., stepped down from the Board, effective as of June 18, 2024. "We are pleased to welcome Svetlana, an experienced and accomplished biopharmaceutical executive, to our B

      6/19/24 8:00:00 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors

      REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced the appointment of Thomas G. Wiggans, a veteran biopharmaceutical executive, as Chairperson of Jasper's Board of Directors (the Board), effective immediately. Bill Lis is stepping down as Chairperson and will re

      11/1/23 8:00:00 AM ET
      $DERM
      $JSPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Jasper Therapeutics Strengthens Management Team with Key Appointments

      Patricia Carlos Appointed Senior Vice President of Regulatory Affairs and Quality Annette Marcantonio Appointed Vice President of Clinical Operations REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of two seasoned pharma industry executives to its regulatory affairs, quality and clinical operations

      8/2/23 8:00:00 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JSPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer Mahal Jeetinder Singh

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      2/18/25 5:31:26 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by President, CEO and Director Martell Ron

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      2/18/25 5:30:52 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Cross Herb

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      2/18/25 5:30:21 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JSPR
    Financials

    Live finance-specific insights

    See more
    • Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

      Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile Mean change in UAS7 from baseline of -26.6 observed in the 240mg single dose cohort at 8 weeks, multiple dosing regimens ≥120mg demonstrated UAS7 change of more than -25 points 100% (N=3) Complete Responses (UAS7 = 0) observed in the 240mg single dose cohort at 8 weeks and 66% maintained Well Controlled disease at 12 weeks Serum tryptase reductions below the lower limit of quantification observed at multiple dose levels Data supports commencement of CSU registrational program expected to commence second half of 2025 Company t

      1/8/25 7:00:37 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

      14 of 15 participants enrolled achieved a clinical response 10 of 12 participants in the 120mg cohort achieved a complete response No serious adverse events; no grade 3 or higher adverse events reported Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort Company to host conference call and webinar today at 8:00 a.m. EDT REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic induci

      10/14/24 7:00:00 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care